Brief: Replicel says rct-01 tendon repair clinical trial shows signs of healing chronic tendon problems
28/03/2017 11:00
March 28 (Reuters) - Replicel Life Sciences Inc RP.V :
* Replicel's successful rct-01 tendon repair clinical trial
shows signs of healing chronic tendon problems
* Replicel Life Sciences-first-in-human clinical study meets
primary endpoint demonstrating product safety, clinical
potential for tendon regeneration, healing
* Replicel Life Sciences Inc - clinical trial met its goal
of establishing a complete safety profile at 6 months
* Replicel Life Sciences Inc - clinical trial showed no
serious adverse events related to study treatment or injection
procedure
Source text for Eikon: ID:nCNWRy6Zqa
Further company coverage: RP.V
((bangalore.newsroom@thomsonreuters.com;))
Recent news on Replicel Life Sciences
See all newsBrief: Replicel Life Sciences Announces Reinstatement Of Trading & Conditional Acceptance For Proposed Transaction
Brief: Replicel Life Sciences Says Replicel Announces A Letter Of Intent For Asset Purchase Agreement
Brief: Replicel Announces Binding Term Sheet For Strategic Investment And U.S. Partnership
Brief: Replicel Announces Its Incoming Board Of Directors
Brief: RepliCel Life Sciences Retains Dermatology Sales And Marketing Executive To Guide Global Commercial Strategy For Automated Dermal Injector